What is Pathios Therapeutics?
Founded in 2017, Pathios Therapeutics operates at the intersection of human genetics and cellular immunology. The company is currently prioritizing the development of GPR65 modulators, identifying this receptor as a critical innate immune checkpoint. By utilizing proprietary insights into GPCR signaling, Pathios aims to transform the treatment landscape for a broad spectrum of cancers. Their operational model relies on a blend of internal scientific expertise and strategic external partnerships, ensuring that their drug discovery programs remain at the cutting edge of pharmaceutical research. The firm's commitment to mapping immune cell signaling positions it as a high-potential player in the competitive biotech sector, specifically within the niche of immuno-oncology.
How much funding has Pathios Therapeutics raised?
Pathios Therapeutics has raised a total of $8.8M across 1 funding round:
Series A
$8.8M
Series A (2019): $8.8M with participation from Canaan and Medical Research Commercialisation Fund
Key Investors in Pathios Therapeutics
Canaan
Canaan is an early-stage venture capital firm that invests in technology and healthcare companies, backing founders from seed through growth stages in areas such as enterprise software, fintech, consumer, biopharma, and digital health.
Medical Research Commercialisation Fund
Brandon BioCatalyst is the largest life science investment fund in Australia and New Zealand, specializing in transforming biomedical research discoveries into medical products that enhance patient outcomes and save lives.
What's next for Pathios Therapeutics?
With the recent infusion of capital, Pathios Therapeutics is well-positioned to transition its GPR65-focused programs into more advanced stages of development. The strategic roadmap likely involves scaling its drug discovery infrastructure and potentially expanding its research scope to address other serious diseases where GPR65 modulation could offer therapeutic benefits. As the company continues to leverage its deep understanding of tumour-associated macrophages, the focus will remain on delivering clinical-grade candidates that address significant unmet medical needs. Investors will be monitoring the firm's ability to translate its scientific insights into tangible therapeutic assets, a critical step for any early-stage biotech firm navigating the complex regulatory and clinical landscape of modern drug development.
See full Pathios Therapeutics company page
